Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 07

35P - Targeting the secreted gelsolin-DNGR-1 dendritic cell axis to enhance anti-cancer therapies

Date

10 Sep 2022

Session

Poster session 07

Topics

Cancer Biology;  Cytotoxic Therapy;  Tumour Immunology;  Translational Research;  Targeted Therapy;  Immunotherapy

Tumour Site

Presenters

Kok Haw Jonathan Lim

Citation

Annals of Oncology (2022) 33 (suppl_7): S4-S18. 10.1016/annonc/annonc1035

Authors

K.H.J. Lim1, E. Giampazolias2, O. Schulz2, N.C. Rogers2, A.C. Wilkins3, E. Sahai3, J. Strid4, C. Reis e Sousa2

Author affiliations

  • 1 Immunobiology Laboratory, The Francis Crick Institute & Imperial College London, NW1 1AT - London/GB
  • 2 Immunobiology Laboratory, The Francis Crick Institute, NW1 1AT - London/GB
  • 3 Tumour Cell Biology Laboratory, The Francis Crick Institute, NW1 1AT - London/GB
  • 4 Department Of Immunology And Inflammation, Imperial College London - Hammersmith Campus, W12 0NN - London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 35P

Background

Type 1 conventional dendritic cells (cDC1) are professional antigen presenting cells and play a critical role in priming cytotoxic CD8+ T cells. DNGR-1 (a.k.a. CLEC9A) is a dedicated cDC1 receptor that binds to F-actin exposed on necrotic cells, signalling to enhance cross-presentation of dead-cell associated antigens. We have recently shown that secreted gelsolin (sGSN), a plasma protein, acts as a negative regulator of DNGR-1 function and dampens anti-cancer immunity (Giampazolias et al. Cell 2021). Here, we investigated the effects of loss of sGSN on various anti-cancer therapies.

Methods

In vivo therapy models were established in C57BL/6 mice: Rag1 –/– (no T/B cells), Batf3 –/– (no cDC1s), sGsn –/–, sGsn –/– Clec9 agfp/gfp and WT (wildtype). Transplantable cell lines used included MCA-205 fibrosarcoma, 5555 BrafV600E melanoma and B16-F10 LA-OVA-mCherry melanoma. Mice received doxorubicin (intratumoural), BRAF-inhibitor PLX4720 (oral gavage), or X-ray irradiation. Bioinformatic analysis of human cancer datasets was done using TCGA Pan-cancer Atlas.

Results

First, we confirmed that tumour control following various therapies requires an immunocompetent host as efficacy was markedly reduced in Rag1 –/– compared to WT mice: (i) MCA-205 + doxorubicin, (ii) 5555 BrafV600E + PLX4720, and (iii) B16-F10 LA-OVA-mCherry + X-ray. Consistently across all these immunogenic therapeutic modalities, loss of sGSN significantly enhanced tumour control compared to treated WT controls. We proved that this is an on-target effect as mice deficient in both sGSN and DNGR-1 behaved similarly to WT mice following therapy. Interrogating n=31 TCGA datasets of solid tumours, we noted that high expression of CLEC9A is associated with better survival in several cancer subtypes.

Conclusions

Utilising preclinical models, we show that mice deficient in sGsn display enhanced responsiveness to chemotherapy, targeted therapy and radiotherapy. Tumours enriched in DNGR-1 may be potential avenues where targeting sGSN could be impactful. Further prospective studies are warranted to identify patients who may benefit most from inhibition of sGSN function to unleash DNGR-1-dependent cross-presentation as a component of more effective combinatorial treatment regimens.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Kok Haw Jonathan Lim and Caetano Reis e Sousa are legally responsible for the governance, coordination and running of the study. K.H.J.L., E.G., O.S., N.C.R. and C.R.S. are named as contributors/inventors on a patent application on the use of sGSN for immunotherapies.

Funding

The Francis Crick Institute, which receives core funding from Cancer Research UK (FC001136), the UK Medical Research Council (FC001136), and the Wellcome Trust (FC001136); an ERC Advanced Investigator grant (AdG 268670); a Wellcome Investigator Award (106973/Z/15/Z); and a prize from the Louis-Jeantet Foundation. K.H.J.L is supported by a Wellcome Imperial 4i Clinical Research Fellowship (216327/Z/19/Z). This research was funded in whole, or in part, by the Wellcome Trust (grants FC001136, 106973/Z/15/Z, and 216327/Z/19/Z).

Disclosure

C. Reis e Sousa: Financial Interests, Personal and Institutional, Member of the Board of Directors, Founder, advisor, stockholder, recipient of research grant: Adendra Therapeutics; Financial Interests, Personal, Advisory Role, Owns stock options and/or paid consultant: Bicara Therapeutics, Montis Biosciences, Bicycle Therapeutics, Sosei Heptares. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.